The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | A Phase II trial of loncastuximab tesirine in previously treated Waldenström’s macroglobulinemia
Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, outlines the promising results of a Phase II trial (NCT05190705) of the antibody-drug conjugate (ADC) loncastuximab tesirine in patients with previously treated Waldenström’s macroglobulinemia (WM). Dr Castillo highlights that this proof-of-concept study, conducted through the WM-NET network, has shown an encouraging efficacy rate at the interim analysis, with the majority of patients responding to the treatment. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
